Fernando et al. conducted a separate analysis when looking at the same four SMARCA4 mutation categories but for patients who received immunotherapy (nivolumab, pembrolizumab, atezolizumab, or durvalumab) at any time during their cancer treatment [11]. This evidence concerns the gene SMARCA4 and cancer.